UBS AG set a GBX 4,550 ($60.46) price target on AstraZeneca plc (LON:AZN) in a report released on Monday, October 9th, www.boersen-zeitung.de reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.
A number of other analysts also recently weighed in on AZN. J P Morgan Chase & Co set a GBX 4,200 ($55.81) target price on AstraZeneca plc and gave the company a neutral rating in a research report on Wednesday, August 9th. Barclays PLC restated an overweight rating and set a GBX 5,500 ($73.08) price objective on shares of AstraZeneca plc in a research report on Monday, August 7th. Jefferies Group LLC dropped their price objective on AstraZeneca plc from GBX 4,900 ($65.11) to GBX 4,400 ($58.46) and set a hold rating for the company in a research report on Tuesday, August 1st. Investec upgraded AstraZeneca plc from a hold rating to a buy rating and dropped their price objective for the stock from GBX 5,000 ($66.44) to GBX 4,900 ($65.11) in a research report on Wednesday, August 9th. Finally, Shore Capital restated a hold rating on shares of AstraZeneca plc in a research report on Monday, October 9th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of GBX 5,172.64 ($68.73).
AstraZeneca plc (LON AZN) opened at 5181.00 on Monday. The company has a 50-day moving average price of GBX 4,859.28 and a 200 day moving average price of GBX 4,907.26. The company’s market capitalization is GBX 65.59 billion. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00.
In other news, insider Nazneen Rahman bought 39 shares of the firm’s stock in a transaction on Thursday, July 27th. The stock was acquired at an average cost of GBX 4,370 ($58.07) per share, with a total value of £1,704.30 ($2,264.55).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with our FREE daily email newsletter.